摘要
探讨ＩＬ－２／ＬＡＫ细胞与放疗和／或化疗联合治疗晚期恶性肿瘤的价值。方法：本组共３０例，其中单纯ＩＬ－２／ＬＡＫ细胞治疗 ５例（包括 ２例ＴＩＬ细胞胸腹腔灌注），ＩＬ－２／ＬＡＫ细胞联合放疗１８例（包括 １例动脉灌注），ＩＬ－２／ＬＡＫ细胞联合化疗４例（包括１例动脉灌注），ＩＬ－２／ＬＡＫ细胞联合放疗和化疗３例。结果：完全缓解率２０．０％（６／３０），总有效率 ５０．０％（１５／３０），其中单纯ＩＬ－２／ＬＡＫ治疗有效率 ２０．０％（１／５），联合治疗有效率 ５６．０％（１４／２５）。２例 Ｋａｐｏｓｉｓ’ｓ肉瘤采用ＩＬ－２／ＬＡＫ细胞联合放、化疗均达完全缓解，１例乳腺癌术后大量胸水用 ＴＩＬ细胞＋ＩＬ－２治疗达完全缓解。结论：ＩＬ－２／ＬＡＫ细胞是有效的肿瘤过继性免疫疗法，和放、化疗联合应用可能有助于提高疗效。
Objective: To evaluate the results of IL-2/LAK cells combination radiotherapy and chemotherapy in the treatment of advanced cancer. Methods: 30 patients of advanced cancer were studied in this trial Of them, 5 patients treated by IL-2/LAK cells alone (2 of 5 patients received TIL cells), 18 patients received IL-2/LAK cells combination radiotherapy (1 of them received artery infusion), 4 patients recei-ved IL-2/ LAK cells combination chemotherapy (1 of them received artery infusion), and 3 patients received IL-2/LAK cells combination radiotherapy and chemotherapy. Results: The overall response rate was 50.0%, (15/30) with a complete response rate of 20.0% (1/5) in IL-2/LAK cells group only, and 56.0% (14/25 ) in combined group. Two patients with Kaposis's sarcoma achieved complete response. Conclusions: This result showed that IL-2/LAK cells for advanced carcinoma are effective, that IL-2/LAK cells combined with radiotherapy and (or) chemotherapy are conducive to good response rate.
出处
《新疆医科大学学报》
CAS
2000年第1期41-43,共3页
Journal of Xinjiang Medical University
